BA enters September having shed another 2.6% on the week to $205.66, extending a slide that has now cost the stock nearly 5% over the past month — yet the frantic options hedging that defined last week's note has quietly pulled back from its peak.
The options mood is less charged than it was. The put/call ratio has eased to 0.92, down from the 0.95 registered on August 26 when it nearly hit three standard deviations above average. It remains elevated — running about 1.5 standard deviations above the 20-day mean of 0.88, and still well clear of where it spent most of July and early August in the 0.84-0.87 range. The 52-week peak of 1.01 is no longer in touching distance. Hedging demand has moderated with the pace of selling, but it has not unwound. Short interest tells the same story it has told for weeks: 2.08% of the free float, up roughly 5% on the week, but low in any absolute sense. Availability is extraordinarily loose at roughly 6,054% — more than 60 shares available to borrow for every one currently lent out — and cost to borrow is a negligible 0.43%. The lending market is not the story here, and it has not been for some time.
The Street diverges sharply from recent price action. The consensus is firmly buy-leaning, with 18 buy ratings against just 5 holds and no sells. More striking is the direction of recent analyst moves: BNP Paribas made a dramatic two-notch upgrade in early August, moving from Underperform all the way to Outperform with a new target of $300. JP Morgan raised its target to $290 after the Q2 print on July 29, maintaining Overweight. Argus Research upgraded to Buy in mid-August with a $265 target. Against that, RBC trimmed modestly to $265 while holding Outperform, and Morgan Stanley kept its more cautious Equal-Weight stance with a $250 target. The mean price target implies around 32% upside from current levels. Factor scores support the bull case on momentum and estimate revisions: EPS momentum over the past 30 and 90 days ranks in the 97th and 98th percentiles respectively, and the analyst recommendation differential scores in the 99th percentile. The forward P/E of roughly 90x and a price-to-book above 16 keep valuation bulls grounded — the multiple has compressed about 22% over the past 30 days as the price has drifted lower, but it remains demanding for a business still in recovery mode. The bulls emphasise the backlog and aviation demand cycle; the bears point to Airbus competition, supply chain execution risk, and legal overhangs.
Institutional ownership gives the bull case structural ballast. BlackRock added nearly 3 million shares through July, reporting a 7.8% stake. Capital Research and Management added close to 10 million shares over the same period, lifting its stake to 5.1%. FMR (Fidelity) has also been a consistent buyer, growing from 5.2% to 7.0% of class across two 13G amendments filed since August 2025. No 13D activists are on the register — all major holders are passive, and the disclosure note applies: stakes are as-last-disclosed around the 5% threshold. The employee savings trust holding roughly 3.9% of shares is unchanged and listed with a stale December 2024 date. On the insider side, the only recent EDGAR activity is a small tax-withholding transaction — an "F" code filing by the CEO of the defense division on August 28, covering just 630 shares at $209. Net insider activity over the past 90 days rounds to zero in both share and dollar terms: no conviction signal in either direction from the C-suite.
Peers offered no shelter this week. GE fell 5.3% and CW dropped 5.2%, making Boeing's 2.6% decline look contained by comparison. SAF gave back 3.5% and TDG shed 3.1%, suggesting broad aerospace and defense selling pressure rather than a Boeing-specific dislocation. HWM was the lone bright spot, gaining 4.1% on the day even as its week finished down 3.5%.
Q3 results are scheduled for October 21. The last print — Q2 on July 28 — produced a 1.2% one-day gain but a 12% rally over the following five sessions, a dynamic that reflects how tightly Boeing's recovery narrative is tied to delivery cadence and cash flow progression. The setup heading into October is one to watch: options hedging has come off the boil but not fully cleared, short interest is slowly rebuilding from a low base, and the stock is now trading roughly $60 below the mean analyst target — a gap that will either close on improved operational execution or remain a ceiling test if production headwinds resurface.
See the live data behind this article on ORTEX.
Open BA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
